Literature DB >> 11554171

Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.

R G Owen1, S L Barrans, S J Richards, S J O'Connor, J A Child, L A Parapia, G J Morgan, A S Jack.   

Abstract

To establish whether a combination of morphologic and immunophenotypic criteria could be developed to more precisely define Waldenström macroglobulinemia (WM) and prognostic factors, we retrospectively assessed the clinical and laboratory features of 111 cases of WM. Bone marrow infiltration by small lymphocytes was documented in each case; and diffuse, interstitial, nodular, and paratrabecular patterns of infiltration were documented in 58%, 32%, 6%, and 4% of cases, respectively. Ninety percent were characterized by a surface immunoglobulin-positive, CD19+CD20+CD5-CD10-CD23- immunophenotype. The median overall survival from diagnosis was 60 months; univariate analysis revealed the following adverse prognostic factors: older than 60 years, performance status more than 1, platelet count less than 100 x 10(3)/microL (< 100 x 10(9)/L), pancytopenia, and diffuse bone marrow infiltration. Associated median survival was 40, 38, 46, 28, and 59 months, respectively. Multivariate analysis revealed age, performance status, and platelet count as prognostically significant, but stratification of patients according to the International Prognostic Index had limited value. We suggest defining WM by the following criteria: IgM monoclonal gammopathy; bone marrow infiltration by small lymphocytes, plasmacytoid cells, and plasma cells in a diffuse, interstitial, or nodular pattern; and a surface immunoglobulin-positive, CD19+CD20+CD5-CD10-CD23- immunophenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554171     DOI: 10.1309/4LCN-JMPG-5U71-UWQB

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

Review 1.  Bone marrow immunohistology of plasma cell neoplasms.

Authors:  A Wei; S Juneja
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 2.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families.

Authors:  Mary L McMaster; Lynn R Goldin; Yan Bai; Monica Ter-Minassian; Stefan Boehringer; Therese R Giambarresi; Linda G Vasquez; Margaret A Tucker
Journal:  Am J Hum Genet       Date:  2006-08-31       Impact factor: 11.025

Review 4.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

5.  Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Authors:  Akio Saito; Atsushi Isoda; Masaru Kojima; Akihiko Yokohama; Yutaka Tsukune; Makoto Sasaki; Shigeki Ito; Akihiro Ohtsu; Michiaki Koike; Kayoko Murayama; Keiichi Moriya; Hideto Tamura; Morio Matsumoto; Hirotaka Nakahashi; Sakae Tanosaki; Tohru Sakura; Toshihide Kawamura; Tomomi Miyanaga; Naoya Nakamura; Hirokazu Murakami; Hiroshi Handa; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2017-07-07       Impact factor: 2.490

Review 6.  The classification of lymphomas: a new beginning or the end of an era?

Authors:  A S Jack
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 7.  [Lymphomas and lymphatic leukemias in the bone marrow].

Authors:  P Adam; L Quintanilla-Fend; F Fend
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

8.  A Diagnostic Dilemma: Waldenström's Macroglobulinemia/Plasma Cell Leukemia.

Authors:  Bhawna Sethi; K S Butola; Yogesh Kumar
Journal:  Case Rep Pathol       Date:  2012-09-09

Review 9.  Epratuzumab in non-Hodgkin's lymphomas.

Authors:  Richard R Furman; Morton Coleman; John P Leonard
Journal:  Curr Treat Options Oncol       Date:  2004-08

Review 10.  Waldenström macroglobulinemia.

Authors:  Irene M Ghobrial; Thomas E Witzig
Journal:  Curr Treat Options Oncol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.